Locus of control flip: management says the outcome is in its own hands, and names what it controls
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that results will be determined mainly by things the company controls, and backs it with a specific named driver already real. Looking at the transcript: Joe Hogan and John Morici discuss Q4 results and 2023 outlook. They mention stability in Americas/EMEA, but also macroeconomic fragility. They say they are not providing full year revenue guidance due to global challenges. They emphasize investments in R&D, new product cycles, and technology platforms. They mention specific things like iTero scanners, Invisalign, DSP subscription programs, and upcoming innovations. However, they also attribute much to external conditions: "macroeconomic environment remains fragile", "uncertainty in China", "consumer confidence" etc. They say "we are cautiously optimistic for continued stability and improving trends as we move through the year" but that depends on external factors. They do mention "we intend to focus on the things we can control and influence, which includes strategic investments in sales, marketing, technology and innovation." That is a stance of controlling what they can, but they also say "assuming no additional material disruptions or circumstances beyond our control" for their margin guidance. They point to specific drivers like new product cycles, but those are future launches? They say "we'll begin to commercialize one of the largest new product and technology cycles in our 25-year history" - that is a plan, not yet in motion? They also mention "In the next 1 to 3 years, you should expect to see new platforms" - that's future. They mention existing things like iTero 5D, scanner rental programs, CPO leasing, Desktop Metal collaboration - that is already real. But do they attribute improvement to these? They say "We continue to develop new capital equipment opportunities" and "we are confident in our large, untapped market opportunity" - but they also say "the macroeconomic situation remains fragile" and "we are not providing full year revenue guidance" because of external uncertainty. The question is whether management conveys that results will be determined mainly by things they control. They say they focus on what they can control, but they also say the environment is the swing factor.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CLVT | Clarivate Plc | Q2 2021 | 2021-07-31 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| SXT | Sensient Technologies Corporation | Q4 2016 | 2017-02-10 | A |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| EFSC | Enterprise Financial Services Corp | Q4 2016 | 2017-01-24 | B+ |
| RPM | RPM International Inc. | Q2 2017 | 2017-01-05 | D |
| LEE | Lee Enterprises, Incorporated | Q4 2016 | 2016-12-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GIS | General Mills, Inc. | Q4 2016 | 2016-06-29 | B+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
TNET · Q1 2024 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing future results as largely self-determined through internal levers like offsetting attrition with new sales (which they expect to "consistently achieve"), disciplined execution in sales/retention/expenses, and a strategy review to align resources for profitable growth. They back this with specific, already-real drivers: 50 % YoY ACV new sales growth, 28 % YoY growth in tenured sales reps plus productivity gains, and nearly positive sequential core WSE growth in Q1. While acknowledging external headwinds (economic hiring softness, insurance cost inflation), they repeatedly redirect to what they control and point to these internal actions as the primary drivers of improvement. The stance is coherent and not generic. Answer: YES. The question requires "mainly" and "rather than by market conditions, etc."; the transcript meets that threshold by repeatedly emphasizing internal control and execution while treating external factors as secondary headwinds they are managing.
GPRO · Q4 2023 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing 2024 results as driven primarily by its own actions: the retail expansion already underway (3,200 doors added, 7,000 targeted), new product launches (four SKUs in 2024), the Forcite acquisition closed this quarter, and the Quik desktop app launched 24 hours ago. They repeatedly tie future growth to these internal levers rather than external demand or macro conditions, while noting external factors only as temporary Q4 headwinds. This meets both criteria. NO if it were mainly external or generic. YES. The stance is coherent and backed by a named, already-real driver (ret 3200 doors + strategy shift). The answer is YES. The question is answered with YES. The final answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES.
HROW · Q4 2021 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing the path ahead as substantially self-determined through its own execution and actions (e.g., "positioning Harrow Health to fulfill its vision," "executing on that vision," "we are expanding our existing commercial infrastructure," "establishing our own internal analytical lab," "we expect to see 2023 number looks like 2024, 2025" via "profits that this team has been able to generate," and "we have that amazing commercial team and we have a large customer base" for launches without dilution). They redirect from external factors like COVID to internal progress and state they will "not dilute our shareholders necessarily to launch AMP-100" due to internal capabilities.